Conference Coverage: EHA 2024 – Focus on Leukemia and Myelodysplastic Syndromes (MDS)
Expert perspectives on the latest therapeutic developments, treatment approaches, and implications for clinical decision-making regarding leukemia
June 24, 2024
Faculty Chair
Elias Jabbour, MD
MD Anderson Cancer Center, Houston, TX, USA
Faculty Members
Aaron Logan, MD, PhD
University of California San Francisco, CA, USA
Naval Daver, MD
University of Texas MD Anderson Cancer Center, Houston, TX, USA
Rami Komrokji, MD
Moffitt Cancer Center, Tampa, FL, USA
Josep-María Ribera, MD, PhD
Catalan Institute of Oncology, Barcelona, Spain
Richard Dillon, MBBS, PhD, MRCP, FRCPath
King’s College London, UK
Valeria Santini, MD
University of Florence, Italy
KEY TAKEAWAYS AND STRATEGIC INSIGHTS
- Advances in Low-Risk MDS
- Advances in High-Risk MDS
- Advances in Newly Diagnosed AML
- Advances in R/R AML
- Advances in Ph+ ALL
- Advances in Ph– ALL
